Shopping Cart
Remove All
Your shopping cart is currently empty
Adintrevimab (ADG20) is a broad-spectrum neutralizing monoclonal antibody targeting SARS-CoV-2. It binds to a highly conserved epitope within the receptor-binding domain (RBD) of the spike glycoprotein, blocking its interaction with the ACE2 receptor. The Fc region is modified to extend its in vivo half-life. Research demonstrates potent neutralizing activity against various variants including Alpha, Beta, Gamma, and Delta, although its activity is significantly reduced against certain Omicron sub-lineages.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $647 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $987 | 2-4 weeks | 2-4 weeks |
| Description | Adintrevimab (ADG20) is a broad-spectrum neutralizing monoclonal antibody targeting SARS-CoV-2. It binds to a highly conserved epitope within the receptor-binding domain (RBD) of the spike glycoprotein, blocking its interaction with the ACE2 receptor. The Fc region is modified to extend its in vivo half-life. Research demonstrates potent neutralizing activity against various variants including Alpha, Beta, Gamma, and Delta, although its activity is significantly reduced against certain Omicron sub-lineages. |
| In vitro | In vitro, Adintrevimab demonstrates potent neutralization against SARS-CoV-2 variants (Alpha to Delta) by binding a conserved RBD epitope, though it shows diminished activity against Omicron BA.1 and lacks activity against BA.2-BA.5 sub-lineages [1]. |
| In vivo | In prophylactic studies using Syrian golden hamsters (5-6-week-old females) infected with SARS-CoV-2/WA1/2020, single intraperitoneal administration of Adintrevimab (9.25 to 2,000 μg, approx. 0.1 to 20 mg/kg) provided dose-dependent protection, significantly reducing lung viral load and alleviating virus-induced lung pathology [1]. |
| Synonyms | ADG 20 |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | SARS-CoV-2 |
| Cas No. | 2516243-54-0 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.